Safety and Efficacy of Thymus Transplantation in Complete DiGeorge Anomaly, IND#9836
Phase: NA
Conditions: Complete DiGeorge Anomaly, DiGeorge Syndrome, DiGeorge Anomaly, Complete DiGeorge Syndrome
Sponsor: Sumitomo Pharma Switzerland GmbH

DocuSign Envelope ID: DE1813FA-F11 B-4O53-A69F-99A8B0B38859 
CLINICAL PROTOCOL, amended 15Apr2022 
Page 1 of 107 
Safety and Efficacy of Thymus Transplantation in Complete DiGeorge Anomaly, IND#9836 
CLINICAL STUDY PROTOCOL 
Safety and Efficacy of Thymus Transplantation in Complete DiGeorge Anomaly 
Development Phase: 
Protocol date 
Sponsor representative: 
Sponsor: 
Protocol No_ 25966 
I/II, IND#9836 
Open label treatment 
Amendment version 15Apr2022 
Enzyvant Therapeutics GmbH 
Viaduktstrasse 8 
Basel, Switzerland 4051 
Confidentiality Statement 
The infonnation contained in this document pa1ticularly m1published data. is the prope1ty or under control of 
Enzyvant Therapeutics GmbH and is provided to you in confidence as an investigator. potential investigator, or 
consultant for review by you. your staff. and an applicable Institutional Review Board or Independent Ethics 
Committee. The info1mation is only to be used by you in com1ection with authorized clinical studies desc1ibed in the 
protocol. You will not disclose any of the info1mation to others without \\ITitten authorization from Enzyvant 
Therapeutics GmbR except to the extent necessa1y to obtain informed consent from those persons to whom the 
investigational product may be administered.